Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Blood Disorders
Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin have to be discontinued and an alternative, nonheparin anticoagulant for HIT treatment must immediately be started. For both the prophylaxis of thrombembolic events in HIT and the treatment of HIT with thrombosis the direct thrombin inhibitor argatroban is approved in the United States. The objective of this review is to describe the mechanism of action and the pharmacokinetic profile of argatroban, to characterize argatroban regarding its safety and therapeutic efficacy and to discuss its place in therapy in HIT.
PDF (468.75 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I am definitely impressed by the manner with which Libertas Academica handled the publication of our research paper. The prompt reviews and other processes involved is a credit to the competence and experience of staff of Libertas Academica. Most outstanding is the friendly communications from the staff which kept us informed all the way through, providing guidance on our submission as it passed through a most rigorous peer review. I would recommend Libertas Academica for ...